Just researching? Get free City Therapeutics mark alerts by email
As of September 27, 2026, City Therapeutics has filed to go public but has not confirmed a listing date. Endpoints News reported on September 25, 2026 that the biotech filed for a Nasdaq initial public offering under the ticker CTY, disclosing $172 million in cash and a Phase 1 trial for its Factor XI siRNA candidate, CITY-FXI. BioSpace, also reporting on September 25, 2026, said the filing was a Thursday SEC filing dated September 24, 2026, and named City Therapeutics part of its 2026 NextGen startup class, the same week ADARx Pharmaceuticals priced a $446.3 million upsized IPO. City Therapeutics was founded in 2023 by former Alnylam CEO John Maraganore, now co-founder and executive chairman, with Andy Orth as CEO; the company raised a $99.5 million Series B in June 2026, backed by ARCH Venture Partners and Regeneron Ventures, following a $135 million Series A in fall 2024, per BioSpace's June 8, 2026 report. Segmara does not sell, broker, or advise on City Therapeutics shares; track SEC EDGAR, the SEC's US-only filing database, and the company's own statements for pricing terms or a trading date.
City Therapeutics filed for a Nasdaq IPO under the ticker CTY, Endpoints News reported on September 25, 2026, disclosing $172 million in cash and a Phase 1 trial for the company's Factor XI siRNA candidate, CITY-FXI. BioSpace, reporting the same day, said the filing was a Thursday SEC filing dated September 24, 2026.
BioSpace named City Therapeutics part of its own 2026 NextGen startup class and noted the filing landed the same week ADARx Pharmaceuticals priced a $446.3 million upsized IPO, which BioSpace described as biotech's third-largest IPO of 2026.
Who is behind City Therapeutics
City Therapeutics was founded in 2023 by John Maraganore, the former CEO of Alnylam Pharmaceuticals, who now serves as co-founder and executive chairman; Andy Orth is CEO, according to BioSpace's June 8, 2026 report.
That report covered a $99.5 million Series B raised in June 2026, backed by ARCH Venture Partners and Regeneron Ventures, which followed a $135 million Series A closed in fall 2024.
What is not yet confirmed
Neither Endpoints News nor BioSpace reported a share price range, an offering size, or a listing date; both describe a filing event dated September 24, 2026, not a completed or priced offering.
SEC EDGAR covers only US filings and is the direct source for confirmation of pricing terms or a trading date, alongside City Therapeutics' own statements. Segmara does not sell, broker, or advise on City Therapeutics shares.
Private-share data lens
Public round-by-round marks are incomplete for this company. Segmara shows the listing mark and keeps the seed-to-IPO analysis focused on verifiable funding, tender, or secondary signals.
Segmara markNo indicative price yet
Indicative listing context
Stage
Date
Valuation / price signal
Why it matters
Seed / early
Private
Not reliably public
Do not invent a seed price when the source set is thin.
Growth rounds
Private
Company and market sources vary
Use public sources and official company releases.
Segmara listing
Current
No indicative price yet
Indicative reference only, not a quote or an offer.
IPO status
Current
No public ticker shown here
Watch official company releases and the free Segmara IPO calendar.
Seed-to-IPO path
Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
Metric
Value
Context
Canonical route
/blog/when-will-city-therapeutics-ipo
Stable URL path for AI and search extraction.
Article title
When Will City Therapeutics IPO? It Just Filed With $172M Cash
Main page topic.
Attached public sources
3
Number of citation links rendered at the bottom of the article.
Segmara listed companies
148
Live private-company listings in the public catalogue.
Priced listings
37
Catalogue listings with visible indicative or direct marks.
Listings without an indicative price
111
Catalogue listings where a public price is intentionally not invented.
Company
City Therapeutics
Named company covered by this page.
Symbol label
CITY
Segmara display symbol; not a public stock ticker unless separately stated.
Sector
Biotech & RNA Medicine
Catalogue sector used for comparison and internal linking.
Listing structure
Request
How the listing is categorized on Segmara.
Segmara mark
No indicative price yet
Visible listing mark, or no indicative price yet.
Sector peer count
1
Number of live Segmara listings in Biotech & RNA Medicine.
Structure peer count
111
Number of live Segmara listings categorized as Request.
Data fingerprint chart
Stage
Timing
Price / valuation signal
Interpretation
Formation
Private
Early ownership
The first value creation happens before ordinary public-market access.
Growth rounds
Private
Institutional repricing
Later rounds and tenders create the price history buyers study.
Segmara listing
Current
No indicative price yet
Indicative reference only, not a quote or an offer.
Exit path
Future
IPO, tender, acquisition, or continued private status
Searches like 'When Will City Therapeutics IPO? It Just Filed With $172M Cash' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.
What counts as a listing step
For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.
Segmara role
Segmara takes reviewed pre-IPO allocation requests funded by Stripe USD credits from $25 ($1.00 starter credit); no allocation is guaranteed. It also publishes dated indicative reference marks across 140+ private companies. Nothing on this page is investment advice.
How pre-IPO share access works
Standard Segmara allocation path
1. SearchStart with the company or pre-IPO question
2. ListingReview indicative mark and structure context
3. CheckoutFund from $25 ($1 starter credit) via Stripe, no password
4. ReviewEach request is reviewed in your dashboard; no allocation is guaranteed
What happens after payment
Indicative mark & listing selectionPublic
No-password StripeFrom $25 / $1 credit
Share allocation requestDirect
Transfer & settlement termsReviewed, not guaranteed
Endpoints News reported on September 25, 2026 that City Therapeutics filed for a Nasdaq IPO under the ticker CTY, disclosing $172 million in cash and a Phase 1 trial for its Factor XI siRNA candidate, CITY-FXI.
BioSpace reported the same day, September 25, 2026, that the filing came via a Thursday SEC filing dated September 24, 2026, and named City Therapeutics part of its 2026 NextGen startup class, the same week ADARx Pharmaceuticals priced a $446.3 million upsized IPO.
City Therapeutics was founded in 2023 by former Alnylam CEO John Maraganore, now co-founder and executive chairman, with Andy Orth as CEO; it raised a $99.5 million Series B in June 2026 from ARCH Venture Partners and Regeneron Ventures, following a $135 million Series A in fall 2024, per BioSpace's June 8, 2026 report.
Risk notes
Rumor risk: unofficial dates, valuations, or funding details circulating on social media or forums are frequently wrong or outdated and should not be treated as confirmation of anything.
Illiquidity risk: any private-market interest, indicative marks, or pre-IPO share arrangements in a company that has not listed can be difficult to exit and may not reflect a tradable price.
Timing risk: a company can pause, restart, or abandon IPO preparation at any stage, including after a confidential or public filing, so no step before pricing guarantees a listing.
Can investors request private-company shares on Segmara?
Yes. Start from $25 ($1.00 starter credit available) in USD portfolio credits via Stripe with no password required, or select a listing across 140+ private companies on Segmara to submit a pre-IPO share allocation request.
Why was this market historically hard for individual investors to reach?
Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes the starting point simpler: browse 140+ named private-company listings, fund USD credits via Stripe from $25 ($1.00 starter credit), and request share allocations with no password wall.
What is the easiest next step?
Start from $25 ($1.00 starter credit available) via instant Stripe checkout (Card, Apple Pay, Link, no password required), or browse Segmara's live pre-IPO listings to select your target company.
Has City Therapeutics confirmed an IPO date?
No. As of September 27, 2026, City Therapeutics has filed to go public on Nasdaq under the ticker CTY, per Endpoints News and BioSpace reporting from September 25, 2026 on a Thursday SEC filing dated September 24, 2026, but no pricing date or share range appears in that reporting.
What exchange and regulator is City Therapeutics filing with?
City Therapeutics filed with the U.S. Securities and Exchange Commission for a listing on the Nasdaq exchange, under the ticker symbol CTY, according to Endpoints News (September 25, 2026). SEC EDGAR covers only US filings and is the direct source to track the registration as it becomes public.
How is City Therapeutics funded so far?
The company raised a $135 million Series A in fall 2024 and a $99.5 million Series B in June 2026, the latter backed by ARCH Venture Partners and Regeneron Ventures, according to BioSpace's June 8, 2026 report. The IPO filing separately disclosed $172 million in cash on hand, per Endpoints News.
Can I buy City Therapeutics shares before the IPO?
Not through Segmara. Segmara does not sell, broker, or arrange purchases of City Therapeutics shares, before or after any IPO.
Pre-IPO Allocation
Request City Therapeutics shares on Segmara.
Start from $25 ($1 starter credit available) via Stripe with no password required, fund USD portfolio credits, and request a pre-IPO allocation in City Therapeutics.